Celgene Corp (CELG)
$108.24 0.00 (0.00%)
19:58 EST CELG Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 76.51B
PE Ratio 30.15
Volume (Avg. Vol.)
Day's Range 108.24 - 108.24
52-Week Range 97.30 - 110.70
Dividend & Yield N/A (N/A)
CELG Stock Predictions, Articles, and Celgene Corp News
- From InvestorPlace
- From the Web
Charles Schwab to purchase TD Ameritrade? Let's look at all of the M&A news making noise in the stock market today.
With FDA Breakthrough Therapy designations and robust drug pipelines, these biotech companies are all stocks to buy for 2020.
Biotech stocks overall are holding up fairly well amid recent market volatility. Look at which four biotech stocks to buy have staying power.
Amgen's purchase of Celgenes blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space and boost Amgen stock.
Trade talks gave a lift to stocks, while Johnson & Johnson will be in focus after the close. Here's what happened in the stock market today.
Celgene news for Thursday about it selling Otezla has CELG stock on the rise as it moves forward with the Bristol-Myers Squibb merger.
BMY stock may continue to bounce around, but the months-long selloff is now slowing because Bristol-Myers Squibb is still thriving.
Stock were hit on Thursday as investors try to parse through a deluge of earnings results. Here's what moved the stock market today.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
AbbVie is buying Allergan, FedEx and Blackberry are reporting earnings and Microsoft is on the move. Here are our top stock trades.
The stock charts of EA, AAP and MGM have run through the technical trading wringer in front of today's action.
Celgene and Bristol-Myers Squibb stocks took a hit, video games rallied and Caesars Entertainment entered into a $17.3 billion merger. Here's the Nasdaq Today report.
Bristol-Meyers Squibb news for Monday has BMY stock taking a beating after announcing a delay to its merger deal with Celgene.
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
Bristol Myers Squibb Co.’s comments that U.S. regulators still haven’t planned to inspect a facility that makes one of its experimental cancer drugs overshadowed news that a filing for another one of its cancer treatments with Bluebird Bio Inc. was accepted for review by the Food and Drug Administration.
From Seeking Alpha
From Talk Markets